FDA Adverse Event Injury Summary report: N

BIASURGE® ADVANCED SURGICAL SOLUTION

MDR report key: 22840037 · Received August 19, 2025

Report

Report Number
3021784063-2025-00001
Event Type
Injury
Date Received
August 19, 2025
Date of Event
July 17, 2025
Report Date
August 18, 2025
Manufacturer
ROCHAL TECHNOLOGIES LLC
Product Code
FRO
PMA / PMN Number
K223377
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
TX, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

AN INVESTIGATION COULD NOT BE COMPLETED BECAUSE THE FACILITY DOES NOT RETAIN THE REQUIRED PRODUCT INFORMATION AND ATTEMPTS TO OBTAIN IT FROM EXTERNAL SOURCES WERE UNSUCCESSFUL. BASED ON THE NUMBER OF UNITS DISTRIBUTED TO DATE AND THE REPORTED INCIDENTS, THE ESTIMATED POTENTIAL INCIDENT RATE IS 0.02%. SURVEILLANCE ACTIVITIES WILL CONTINUE TO ASSESS ANY EMERGING TRENDS OR ADDITIONAL REPORTING.

Description of Event or Problem · 0

CASE (B)(4) (B)(6) 2025: 87-YEAR-OLD MALE WITH CECAL OBSTRUCTION. OPEN HEMI-COLECTOMY WAS PERFORMED. NO UNUSUAL PROCEDURE COMPLICATIONS WERE NOTED. AT THE COMPLETION OF THE CASE AND PRIOR TO CLOSURE BIASURGE® WAS USED. BIASURGE WAS INSTILLED USING GRAVITY FLOW WITHOUT PULSE LAVAGE. IT WAS DELIVERED TO THE PERITONEAL CAVITY BY GRAVITY LAVAGE, DWELL TIME WAS ONE TO TWO MINUTES, AND THE FLUID WAS THEN SUCTIONED OUT OF THE CAVITY PRIOR TO CLOSURE. THE SURGEON STATED THAT THE FLUID WAS NOT WARMED PRIOR TO INSTILLATION. ANESTHESIA NOTED SIGNIFICANT HYPOTENSION WITHIN MINUTES WITH A BLOOD PRESSURE DROP TO 40/20. FLUID BOLUSES AND VASOPRESSORS WERE USED. PATIENT STABILIZED AND SENT TO RECOVERY ROOM. HE HAD ELEVATED TROPONIN CARDIAC ENZYMES POST-OPERATIVELY AND REMAINS HOSPITALIZED AS OF (B)(6) 2025. THE SURGEON INITIALLY ATTRIBUTED THIS SCENARIO TO THE PATIENT'S AGE AND HEALTH STATUS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
252553 BIASURGE® ADVANCED SURGICAL SOLUTION DRESSING, WOUND, DRUG FRO ROCHAL TECHNOLOGIES LLC BAS-0101 UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 87 YR Male Required Intervention| H| L